Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation: The new Museum Director of Amos Rex will be announced Friday November 17th

Amos Rex, which burst onto the scene with a bang in 2018, has established itself as an unconventional art museum and a landmark in Helsinki, bringing playfulness into the art scene. The board of Amos Rex has searched for a new Museum Director for Amos Rex through an international recruitment process. The new Museum director has been chosen and the decision will be announced Friday November 17th. Amos Rex. Photo: Mika Huisman   Welcome to the press event on Friday November 17th at 10–11 am (EET/UTC+2) at the Bio Rex cinema, Mannerheimintie 22-24. The speeches will begin

Impero releases 2023-Q3 Report: Achieved 38% growth in ARR (YoY). For the first three quarters of the year, revenue increased by 41% while capacity costs decreased by 1%

Company Announcement No. 11-2023 Copenhagen, 14 November 2023 At the end of 2023-Q3, Impero realized a 38% year-on-year Annual Recurring Revenue (ARR) growth rate and continued to demonstrate solid SaaS metrics. Revenue for the first three quarters of 2023 increased by 41%, while capacity costs (other external expenses and staff costs) decreased by 1%, contributing to the planned improvement in EBITDA and lower cash-burn from operations. Impero maintains guidance for the full year of 2023, with ARR within the DKK 29M to 33M range and EBITDA expected within the DKK -13M to -11M range.

Flowscape receives order in the UK

A global software company headquartered in London has chosen Flowscape as its booking system to support their hybrid way of working. The order value for one of the company's offices in the UK is GBP 27,000 (SEK 360,000) in the first year and GBP 14,800 (SEK 197,400) annually thereafter."Yet another global company with high demands on function and safety chooses Flowscape, which shows that we have a very competitive offering. Among other things, the customer asked for an efficient solution for desk bookings , and our Desk Sensor with

BioStock: Neola’s CEO: “The doors open for us in the US”

Lund-based Neola Medical released its report for the third quarter last week. The company’s efforts to establish itself on the US market have begun to bear fruit and they have also presented promising clinical data that further strengthens their lung monitoring system Neola. BioStock has reached out to CEO Hanna Sjöström to get her thoughts on the past quarter and to find out what happens next.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/neolas-ceo-the-doors-open-for-us-in-the-us/ This is a press release from BioStock -

AcouSort publishes an information memorandum in connection with the forthcoming rights issue of units

AcouSort AB (publ) ("AcouSort" or the "Company") today publishes an information memorandum regarding the Company's forthcoming rights issue of so-called units (“Units”) consisting of shares and warrants, resolved by the Board of Directors on 7 November 2023 (the "Rights Issue"). The information memorandum is available on the Company's website (www.acousort.com) and on Erik Penser Bank's website (www.penser.se). Upon full subscription in the Rights Issue the Company will initially receive approximately MSEK 24.8 before issuing costs.THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR

Stayble Therapeutics publishes interim report for the third quarter of 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached document and on the Company's website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.Summary   Highlights during the third quarter (July – September 2023) · In July, Stayble announced that about 90% of the patients in the ongoing Phase IIb study for treating degenerative disc diseases have completed their twelve-month follow-up. · In August, the first patient was included

Rejlers receives renewed confidence from Aurora: signs EPC contract for new industrial project in Finland

Rejlers has signed a significant engineering, procurement and construction contract (EPC) with Aurora Kilpilahti concerning engineering, construction and testing of the new substation in the Kilpilahti area in Porvoo, Finland. The substation will expand and strengthen Aurora’s electricity network in the Kilpilahti business area, an important hub for circular economy in the Nordic region. The project is expected to be completed in spring 2025.The agreement signed includes the electrical engineering of the transformer substation, the design and construction of the building itself, and all

Brain+ and VIA University College start usability study on CST-Therapist Companion in Denmark

INVESTOR NEWS · Therapists from 5 Danish municipalities will participate in the study and deliver Cognitive Stimulation Therapy (CST) to people with dementia, using the new version of Brain+’ digital CST-Therapist Companion. · CST-Therapist Companion offers time effective and tailored high-quality delivery of CST, and the study objective is to get structured user feedback on the content and functionalities of the product.   · The usability study is expected to complete by mid-December with final results available in January 2024 to feed into the completion and medical device

Quickbit provides an update on the Board's intention to propose a directed share issue to certain board members, senior executives and certain other employees in the company

Today, November 14, 2023, Quickbit eu AB (publ) announces that the Board of Quickbit no longer intends to propose a directed share issue to certain board members, senior executives and certain other employees of the company who were subject to a trading prohibition during the recently completed rights issue. Instead, these persons intend to investigate the possibility of, together with additional interested parties, acquiring a substantial share of the shares subscribed by the guarantors in the rights issue.On October 31, Quickbit announced that the Board intended to propose a directed

XMReality has resolved on a directed share issue of approximately SEK 5.95 million at a subscription price of SEK 0.43

The Board of Directors of XMReality AB (publ) (“XMReality” or the “Company”) has, with authorization from the annual general meeting held on May 4, 2023, resolved on a directed share issue of 13 834 884 shares at a subscription price of SEK 0.43 per share to Investment AB Spiltan, Rotakorn Electronics Holding AB, Rambas AB and certain other existing well-capitalized and reputable shareholders (the “Directed Share Issue”). Through the Directed Share Issue, XMReality will be provided with approximately SEK 5.95 million before transaction costs.The Directed Share Issue comprises 13 834 884 new

Sigrid Therapeutics Launches the Glucose Stabiliser in the U.S.

Designed to Control Blood Sugar and Weight Without Prescriptions, The Glucose Stabiliser is a Natural Silica-Based Solution. MIAMI, USA - November 14, 2023. Sigrid Therapeutics has officially launched the Glucose Stabiliser, an over-the-counter blood sugar control supplement which reduces caloric intake from fats and carbs. With about 1 in every 10 Americans facing a Type 2 Diabetes diagnosis  and the ever-growing popularity of a class of drugs used for

BioStock: PHI’s CEO reflects on the Company’s momentum

Medtech company PHI has experienced a dynamic year, with multiple significant advancements resulting in a 230 per cent surge in the company’s stock price so far this year. BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.Read the full interview with Patrik Eschricht at biostock.se: https://www.biostock.se/en/2023/11/phis-ceo-reflects-on-the-companys-momentum/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Sweco wins 250 MSEK contract for new metro line in Stockholm

Sweco has been awarded a new contract in connection to the ongoing expansion of the Stockholm metro. The client is Region Stockholm which is making one of the largest ever investments in the Stockholm metro network. The new contract follows several other projects that Sweco has carried out for the new Stockholm metro line since 2014.Stockholm’s metro network handles over 1.1 million passengers daily and is planned to be expanded significantly as the region is growing rapidly. Since 2014, Sweco and Spanish partner TYPSA, have successfully provided services such as architectural, civil and

Read original

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Third quarter (July-September 2023) · Operating profit/loss totaled SEK -5,149,440 (-7,028,100). · Loss for the period totaled SEK -5,046,574 (-7,118,476). · Cash flow from operating activities totaled SEK -14,243,671 (-4,875,926). · Earnings per share before dilution totaled SEK -0.16 (-0.36). Earnings per share after dilution amounted to SEK - 0.16 (-0.36).   Period (January-September 2023) · Operating profit/loss totaled SEK -11,881,583 (-15,410,951). · Loss for the period totaled SEK -11,648,755 (-15,540,291). · Cash flow from operating activities totaled

Update on PACIFIC-2 Phase III trial for Imfinzi

14 November 2023 Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer The PACIFIC-2 Phase III trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of progression-free survival (PFS) versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer (NSCLC). Imfinzi sequentially administered after platinum-based CRT is the established,

Shape Robotics has submitted application for Nasdaq Copenhagen Main Market

Company Announcement No. 37-23Copenhagen, 14. November 2023 With reference to company announcement no. 85-2022 and 97-2022, Shape Robotics today announces initiation of the process for admission to trading and official listing of Shape Robotics’ shares on Nasdaq Copenhagen Main Market Shape Robotics has submitted an application for deletion of its shares from trading on Nasdaq First North Growth Market Denmark in connection with and conditional upon an application for its shares to be admitted to trading and official listing on Nasdaq Copenhagen Main Market under the Shape Robotics’

Dicot initiates repeated dosing in its clinical study

Press release: Uppsala, November 14, 2023. The potency drug developer Dicot's phase 1 study is now entering its second and final part. After the previously announced start of recruitment of participants to what is called MAD, the dosing itself is now ready to start, where the participants will receive multiple doses.Tomorrow morning, the first participants in Dicot's second and final part of its phase 1 clinical trial will be dosed. Initially, participants were given a single dose (called Single Ascending Dose, SAD). Now new participants will receive repeated dosing (Multiple Ascending Dose,

Repurchases of shares by Concentric AB during week 45, 2023

Between 6 November 2023 and 10 November 2023 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 38,735 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Ruukki and Honkarakenne first in the world to implement a roof made of fossil-free steel

Ruukki ConstructionPress release14.11.2023Ruukki Construction, part of the SSAB Group, is partnering with Honkarakenne to pilot the use of SSAB fossil-free steel in roofing products. The first-ever roof made of fossil-free steel will be installed on a Honka log house in Klaukkala, Finland. The piloting is part of Ruukki's efforts to take the construction industry towards carbon-neutral buildings.   The world's first house featuring a roof made of fossil-free steel will be built in Klaukkala, Finland. Manufactured at Ruukki's Vimpeli plant in Finland, the Ruukki Classic roof, is made

Quartiers successfully completes sale of Altura160 project

Quartiers Properties AB (publ) ("Quartiers" or "the Company") has completed the sale of the Altura160 project in Benahavís to Taylor Wimpey de España S.A.U ("Taylor Wimpey") as planned. This transaction, with a value in EUR equivalent of SEK 107.2 million, marks an important milestone for Quartiers and demonstrates the Company's ability to create and realise value in its projects.Through this transaction, Taylor Wimpey, one of the UK's largest residential developers with significant operations in Spain, has taken over ownership of Altura160. The transaction gives Taylor Wimpey the

Change in Eltel's Group Management Team – Caroline Lindgren new General Counsel

Caroline Lindgren has been appointed as the new General Counsel and Head of Sourcing at Eltel and will be a member of the Group Management Team. Caroline will assume her role no later than 1 February 2024.Caroline has 20 years of experience in securities law and corporate law, commercial agreements, compliance, and M&As. She currently serves as Head of Legal at Sweco Sweden. Previously, Caroline has also been an attorney at Mannheimer Swartling Advokatbyrå. – Caroline possesses the experience and qualities needed for this role and I am convinced her leadership will contribute to taking

NCC to renovate Finland’s National Museum

NCC has been contracted by Senate Properties to renovate Finland’s National Museum in Helsinki. The order value is approximately SEK 320 million. Illustration: Museovirasto This construction project is the largest in the museum’s hundred-year history and will create, for example, more space for expanded museum operations. Since June, the parties have been engaged in planning the project and producing construction documents. The construction contract has now been signed, and the renovation can commence. NCC’s assignment includes renovating the roof and facades as well as

Irisity AB (publ) maintains a trajectory of growth, with third-quarter revenues significantly higher and net sales continuing to grow throughout the year.

The CEO comments on the third quarter:   Irisity reports significant YoY growth, with Q3 revenues up by 143% and net sales increasing by 19% for the first three quarters of 2023. We have achieved a second consecutive quarter of positive EBITDA, while continuing to uphold a robust gross margin.   Our current financial position includes cash and credit facilities totaling 31.4 MSEK, which encompasses the recent directed share issue of 39 MSEK resolved at the EGM on October 10. The net result was negative because of large amortization of goodwill and intangible assets after the

Implantica takes a big step forward at its 2[nd] Annual RefluxStop™ Users Meeting

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces a very successful 2[nd] Annual RefluxStop™ Users Meeting in Milan, Italy in early November, where top surgeons from around the world gathered for dialogue and learning on the RefluxStop™ procedure and driving positive patient outcomes.Implantica conducted its second global users meeting discussing clinical and commercial advancements of RefluxStop™ therapy involving more than 50 attendees including current and also upcoming RefluxStop™ surgeons as well as gastrointestinal

There are no items matching the current filter
There are no more items matching the current filter
Back to top